Oncology

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

Experts discuss immunotherapy overlap, nutrition challenges, and clinical judgment with GLP-1 RA use.

Formal preceptor leadership pathways can reduce RPD burden and improve resident support across programs.

Oncology pharmacists face profound ethical tensions, often without formal training to navigate them.

Survivor and pharmacist Kelly Gable, PharmD, BCPP, FAAPP, explains the overlooked challenges shaping patients’ day-to-day lives.

Experts detail the workflows and decisions behind launching complex bispecific therapies.

Multicenter data suggests dexamethasone may safely replace tocilizumab for low-grade CRS.

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.

Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.

Practical insights for navigating rare, high-stakes toxicities.

Expert insights on toxicity management, resistance mechanisms, and frontline integration of Bruton tyrosine kinase inhibitors in MCL.

New data, emerging targets, and evolving ADC use are reshaping second-line decisions.

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

ABBV-744 BD2-selective BET inhibitor shows early spleen and symptom gains with manageable cytopenias in a phase 1b trial.

Matthew Warrick, PharmD, BCPS, BCOP, discusses mechanisms, safety nuances, and practical considerations shaping bispecific antibody use in lymphoma care.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.

Oncology pharmacist Emma Jones, PharmD, BCOP, outlines how clinicians can recognize and manage these complex cases.

A dual-center retrospective study compares 2 fludarabine washout strategies to assess their impact on neutrophil engraftment, infections, growth factor use, and hospital length of stay.

The indication is for patients who have received 1 to 3 prior systemic treatment regimens, of which at least 1 includes bevacizumab.

Disha Patel, PharmD, discusses current data on G-CSF use during HiDAC consolidation for AML, addressing relapse concerns, infection risk, clinical decision-making, and why practice patterns remain divided across institutions.

Pharmacists guide HR+ breast cancer CDK4/6 therapy, tackling interactions, costs, and toxicity monitoring, and applying new clinical trial insights.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.